Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
20 Results for "
Collagen cross-linking
" in MedChemExpress (MCE) Product Catalog:
Products (20)
20 Results for "Collagen cross-linking" in MCE Product Catalog:
18
18 Cited Publications
Synonyms: Di-β-aminopropionitrile fumarate; β-Aminopropionitrile fumarate; β-Ammoniumpropionitrile hemifumarate
3-Aminopropionitrile fumarate (2:1) is a lathyrogen which inhibits crosslinking of collagen.
8
8 Cited Publications
Synonyms: HOSu; 1-Hydroxy-2,5-pyrrolidinedione
Cat. No.: HY-158231
Synonyms: F127DA
Cat. No.: HY-29035
CAS No.: 201610-44-8
Dopamine acrylamide, a polyphenol derivative, can cross-link collagen mainly via noncovalent bonding under acidic-non-oxidized conditions .
Cat. No.: HY-P99047
CAS No.: 1318075-13-6
Synonyms: AB 0024; GS 6624
Target:
Research Areas:
Cat. No.: HY-W243303J
CAS No.: 9003-01-4
Cat. No.: HY-171955
CAS No.: 315705-04-5
Research Areas:
LXG6403 is an orally active and irreversible LOX inhibitor (IC50 = 1.3 μM). LXG6403 is ~3.5-fold more specific for LOX than LOXL2 and does not inhibit LOXL1. LXG6403 inhibits FAK signaling and induces ROS generation and DNA damage, leading to G1 arrest and apoptosis in chemoresistant triple-negative breast cancer (TNBC) cell lines. LXG6403 alters the extracellular matrix (ECM) and collagen structure, reducing collagen cross-linking and deposition, thereby increasing drug penetration and reducing tumor stiffness. LXG6403 overcomes Doxorubicin (HY-15142) resistance in chemoresistant TNBC PDX in vivo and can be used to study high-stiffness resistant tumors .
Cat. No.: HY-113033
CAS No.: 124505-87-9
Target:
Cat. No.: HY-170538
CAS No.: 2125956-92-3
Target:
Research Areas:
SNT-5382 is a lysyl oxidase family (LOX) inhibitor and anti-fibrotic agent. SNT-5382 binds to the LTQ cofactor of LOXL2 and inhibits the enzymatic activities of LOXL3, LOXL4, LOXL1, CYP2C9, and CYP2C19. SNT-5382 reduces cardiac and liver fibrosis as well as collagen crosslinks, and improves cardiac function. SNT-5382 can be used for the research of heart failure, myocardial infarction, and nonalcoholic steatohepatitis-related liver fibrosis .
Target:
Research Areas:
PXS-4787 hydrochloride is a specific and effective pan-LOX (lysyl oxidase) inhibitor for abolishing lysyl oxidase activity. PXS-4787 hydrochloride inhibits LOX with IC50s of 2 μM (Bovine LOX), 3.2 μM (rh LOXL1), 0.6 μM (rh LOXL2), 1.4 μM (rh LOXL3), 0.2 μM (rh LOXL4), respectively. PXS-4787 hydrochloride reduces deposition and crosslinking of collagen I secreted by human fibroblasts .
Cat. No.: HY-P0284
CAS No.: 162929-64-8
Target:
Research Areas:
Cat. No.: HY-P0284A
Target:
Research Areas:
Cat. No.: HY-W740191
CAS No.: 32619-23-1
Synonyms: DHLNL
Target:
Research Areas:
Dihydroxylysinonorleucine is a reducible lysine-derived cross-link. Dihydroxylysinonorleucine can be used for the cross-linking of Collagen .
Cat. No.: HY-180581
Target:
Research Areas:
LOXL2/sGC modulator-1 (Compound 11k) is a LOXL2 inhibitor (IC₅₀ = 0.13 μM) and an sGC activator. LOXL2/sGC modulator-1 shows good selectivity for LOX (IC₅₀ > 45.9 μM) and LOXL3 (IC₅₀ = 1.30 μM). LOXL2/sGC modulator-1 significantly increases intracellular cGMP levels in the presence of the gGC inhibitor ODQ (HY-101255). LOXL2/sGC modulator-1 significantly inhibits hypoxia-induced collagen deposition and cross-linking, while promoting vasodilation. LOXL2/sGC modulator-1 can be used for the study of pulmonary arterial hypertension .
Cat. No.: HY-185931
CAS No.: 3083163-26-9
Target:
Research Areas:
Romolisiran is a sulfotransferase 15 (CHST15) synthesis inhibitor. CHST15 is upregulated in fibrosis (lung, liver, kidney), tumor stroma and inflammation; chondroitin sulfate chains modified by its product participate in TGF-β activation, collagen cross-linking and fibroblast activation. Romolisiran can be used to study diseases associated with fibrosis/stromal modification .
Cat. No.: HY-183644
Target:
Research Areas:
LNO 9 is an orally active LOXL2 inhibitor and NO donor, with an IC50 of 0.17 μM against human LOXL2. LNO 9 competitively binds to the LTQ cofactor of LOXL2 to form an irreversible complex, thereby inhibiting collagen oxidation and abnormal cross-linking. LNO 9 releases nitric oxide (NO) to increase cGMP levels in pulmonary artery smooth muscle cells. LNO 9 inhibits hypoxia-induced collagen modification and possesses vasodilatory activity. LNO 9 ameliorates right ventricular hypertrophy and pulmonary artery medial thickness in rat models induced by hypoxia and Monocrotaline (HY-N0750), and can be used for research on pulmonary hypertension .
Cat. No.: HY-P0284B
Target:
Research Areas:
Cat. No.: HY-W738852
Cat. No.: HY-180560
CAS No.: 2924181-95-1
Target:
Research Areas:
PHD-IN-5 (ISM4808) is an orally active PHD inhibitor that can be used for studying anemia in chronic kidney disease .
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
